Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513526 · ClinicalTrials.gov registry record · Phase 2
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00513526 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 112 participants.
The verdict
NCT00513526, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
Interventions
- BIOLOGICAL Gardasil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513526
The ClinicalTrials.gov registry entry for NCT00513526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gardasil is the first listed.
NCT00513526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513526 about?
NCT00513526 is a clinical study titled "Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection". RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
What is the current status of trial NCT00513526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2007-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00513526?
The interventions under investigation include: Gardasil (BIOLOGICAL).
Who is sponsoring clinical trial NCT00513526?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.